Development of anti-glomerular basement membrane glomerulonephritis during the course of IgA nephropathy: a case report. 2019

Tadasu Kojima, and Go Hirose, and Shuuhei Komatsu, and Taito Oshima, and Kentaro Sugisaki, and Tomohiro Tomiyasu, and Noriko Yoshikawa, and Muneharu Yamada, and Takashi Oda
Department of Nephrology and Blood Purification, Kidney Disease Center, Tokyo Medical University Hachioji Medical Center, 1163 Tatemachi, Hachioji, Tokyo, 193-0998, Japan.

Anti-glomerular basement membrane (GBM) glomerulonephritis does not usually coexist with another glomerulonephritis such as IgA nephropathy. We present a rare case having a combination of these two diseases, and furthermore, histological evaluation could be performed before and after the development of anti-GBM glomerulonephritis over a period of only10 months. A 66-year-old woman was admitted with complaints of microscopic hematuria and mild proteinuria for the past 3 years. Serum creatinine level was normal at that time. The first renal biopsy was performed. Light microscopy revealed mesangial proliferative glomerulonephritis with fibro-cellular crescents in one out of 18 glomeruli, excluding one global sclerotic glomerulus. Immunofluorescence (IF) showed IgA and C3 deposition in the mesangium. Therefore, the diagnosis was IgA nephropathy. Eight months later, the patient's serum creatinine suddenly rose to 4.53 mg/dL and urinalysis showed 100 red blood cells per high power field with nephrotic range proteinuria (12.3 g/gCr). The serological tests revealed the presence of anti-GBM antibody at the titer of 116 IU/mL. Treatments were begun after admission, consisting of hemodialysis, plasma exchange, and intravenous methylprednisolone pulse therapy. At 4 weeks after admission, the second renal biopsy was performed. Light microscopy revealed crescents in 18 of 25 glomeruli, excluding six global sclerotic glomeruli. IF showed linear IgG deposition along the GBM in addition to granular IgA and C3 deposition. Based on these findings, the diagnosis of anti-GBM glomerulonephritis and IgA nephropathy was confirmed. Renal function was not restored despite treatment, but alveolar hemorrhage was prevented. We report a patient with a diagnosis of anti-GBM disease during the course of IgA nephropathy. This case strongly suggests that the presence of autoantibodies should be checked to rule out overlapping autoimmune conditions even in patient who have previously been diagnosed with chronic glomerulonephritis, such as IgA nephropathy, who present an unusually rapid clinical course.

UI MeSH Term Description Entries
D007070 Immunoglobulin A Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions. IgA,IgA Antibody,IgA1,IgA2,Antibody, IgA
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D008775 Methylprednisolone A PREDNISOLONE derivative with similar anti-inflammatory action. 6-Methylprednisolone,Medrol,Metipred,Urbason,6 Methylprednisolone
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010951 Plasma Exchange Removal of plasma and replacement with various fluids, e.g., fresh frozen plasma, plasma protein fractions (PPF), albumin preparations, dextran solutions, saline. Used in treatment of autoimmune diseases, immune complex diseases, diseases of excess plasma factors, and other conditions. Exchange, Plasma,Exchanges, Plasma,Plasma Exchanges
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D005260 Female Females
D005920 Glomerular Mesangium The thin membranous structure supporting the adjoining glomerular capillaries. It is composed of GLOMERULAR MESANGIAL CELLS and their EXTRACELLULAR MATRIX. Mesangium, Glomerular,Mesangial Extracellular Matrix,Extracellular Matrices, Mesangial,Extracellular Matrix, Mesangial,Glomerular Mesangiums,Matrices, Mesangial Extracellular,Matrix, Mesangial Extracellular,Mesangial Extracellular Matrices,Mesangiums, Glomerular
D005922 Glomerulonephritis, IGA A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE. Berger Disease,Immunoglobulin A Nephropathy,Nephropathy, IGA,Berger's Disease,IGA Glomerulonephritis,IGA Nephropathy,Iga Nephropathy 1,Nephritis, IGA Type,Bergers Disease,Glomerulonephritides, IGA,IGA Type Nephritis,Nephropathy 1, Iga,Nephropathy, Immunoglobulin A

Related Publications

Tadasu Kojima, and Go Hirose, and Shuuhei Komatsu, and Taito Oshima, and Kentaro Sugisaki, and Tomohiro Tomiyasu, and Noriko Yoshikawa, and Muneharu Yamada, and Takashi Oda
April 2022, World journal of clinical cases,
Tadasu Kojima, and Go Hirose, and Shuuhei Komatsu, and Taito Oshima, and Kentaro Sugisaki, and Tomohiro Tomiyasu, and Noriko Yoshikawa, and Muneharu Yamada, and Takashi Oda
February 2014, Clinical nephrology,
Tadasu Kojima, and Go Hirose, and Shuuhei Komatsu, and Taito Oshima, and Kentaro Sugisaki, and Tomohiro Tomiyasu, and Noriko Yoshikawa, and Muneharu Yamada, and Takashi Oda
May 2013, CEN case reports,
Tadasu Kojima, and Go Hirose, and Shuuhei Komatsu, and Taito Oshima, and Kentaro Sugisaki, and Tomohiro Tomiyasu, and Noriko Yoshikawa, and Muneharu Yamada, and Takashi Oda
May 2016, Experimental and therapeutic medicine,
Tadasu Kojima, and Go Hirose, and Shuuhei Komatsu, and Taito Oshima, and Kentaro Sugisaki, and Tomohiro Tomiyasu, and Noriko Yoshikawa, and Muneharu Yamada, and Takashi Oda
August 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Tadasu Kojima, and Go Hirose, and Shuuhei Komatsu, and Taito Oshima, and Kentaro Sugisaki, and Tomohiro Tomiyasu, and Noriko Yoshikawa, and Muneharu Yamada, and Takashi Oda
January 2018, Nefrologia,
Tadasu Kojima, and Go Hirose, and Shuuhei Komatsu, and Taito Oshima, and Kentaro Sugisaki, and Tomohiro Tomiyasu, and Noriko Yoshikawa, and Muneharu Yamada, and Takashi Oda
January 2013, Arkhiv patologii,
Tadasu Kojima, and Go Hirose, and Shuuhei Komatsu, and Taito Oshima, and Kentaro Sugisaki, and Tomohiro Tomiyasu, and Noriko Yoshikawa, and Muneharu Yamada, and Takashi Oda
January 2024, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,
Tadasu Kojima, and Go Hirose, and Shuuhei Komatsu, and Taito Oshima, and Kentaro Sugisaki, and Tomohiro Tomiyasu, and Noriko Yoshikawa, and Muneharu Yamada, and Takashi Oda
November 2019, Journal of pathology and translational medicine,
Tadasu Kojima, and Go Hirose, and Shuuhei Komatsu, and Taito Oshima, and Kentaro Sugisaki, and Tomohiro Tomiyasu, and Noriko Yoshikawa, and Muneharu Yamada, and Takashi Oda
May 2021, Medicine,
Copied contents to your clipboard!